PLA2G7 and coronary artery disorder: We found that none was related to CHD risk, suggesting that Lp-PLA2 enzyme activity is unlikely to be causally relevant to CHD, a conclusion concordant with results from two phase 3 trials of a pharmacological Lp-PLA2 enzyme inhibitor.